Bharat Biotech Gets DCGI Nod For Phase 3 Trials Of Its Intra-Nasal COVID-19 Vaccine
Covaxin Phase 3 Trial Data Shows 77.8 Per Cent Efficacy Against Symptomatic COVID, Finds Study Published In Lancet
